Related Experiment Video
Updated: Jun 26, 2026
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Intrathecal corticosteroids might slow Alzheimer's disease progression
1Marshfield Clinic Research Foundation. Marshfield Clinic-Thorp Center, Marshfield, Wisconsin, USA. alisky.joseph@marshfieldclinic.org/
Neuropsychiatric Disease and Treatment
|February 3, 2009
Summary
High-dose steroids may slow Alzheimer's progression. This research proposes intrathecal corticosteroids as a potential Alzheimer's disease treatment, possibly combined with other therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Previous anti-inflammatory drug trials for Alzheimer's disease (AD) have yielded disappointing results.
- Higher-dose steroids have shown potential by reducing amyloid secretion in some patients.
- Case reports suggest dexamethasone may induce remission in amyloid angiopathy.
Purpose of the Study:
- To hypothesize that pulse-dosed intrathecal methylprednisolone or dexamethasone can slow Alzheimer's disease progression.
- To explore the potential additive effects with existing AD treatments like cholinesterase inhibitors and memantine.
- To propose a clinical trial protocol for evaluating intrathecal corticosteroids in AD.
Main Methods:
- Review of existing literature on steroid efficacy in AD and related conditions.
- Formulation of a treatment protocol based on regimens used for multiple sclerosis and CNS lupus.
- Hypothetical model for intrathecal corticosteroid administration in AD.
Main Results:
- Higher-dose steroids significantly reduced amyloid secretion in a small group of non-demented patients.
- A case report indicated complete remission of amyloid angiopathy after dexamethasone treatment.
- The study hypothesizes a detectable slowing of AD progression with intrathecal corticosteroids.
Conclusions:
- Intrathecal corticosteroids (methylprednisolone or dexamethasone) are hypothesized to slow Alzheimer's disease progression.
- This approach may offer benefits additive to current Alzheimer's treatments.
- Intrathecal corticosteroids could become a component of multi-agent therapy for AD and other neurodegenerative disorders.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...